{
  "docId": "019de073-1738-7156-b731-07c93efa817d",
  "docSlug": "021004658348e6f64ef3dd1b50dc5a22",
  "documentTitle": "argenx SE | Results Presentation Deck | 16 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 16,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-step process flow to summarize the clinical and regulatory strategy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-1738-7156-b731-07c93efa817d/5",
  "deckHref": "/decks/019de073-1738-7156-b731-07c93efa817d",
  "deckJsonHref": "/decks/019de073-1738-7156-b731-07c93efa817d.json",
  "deckAnchorHref": "/decks/019de073-1738-7156-b731-07c93efa817d#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.18,
        "x": 0.03,
        "y": 0.4
      },
      "kind": "image",
      "text": "adapt SC myasthenia gravis study",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed649f62-c24f-44d4-a8a0-625e2467445c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.18,
        "y": 0.3
      },
      "kind": "list",
      "text": "Leveraged PK/PD from ADAPT: Leveraged correlation between pharmacodynamic and clinical effect as observed in ADAPT",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ddfdf7b-4ce8-4c9e-9956-204ffc6e4d79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.18,
        "y": 0.75
      },
      "kind": "list",
      "text": "2023 Launch: BLA to be submitted by end of 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "744037a8-5277-4b22-a90a-941df5f69003",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.18,
        "y": 0.45
      },
      "kind": "list",
      "text": "Met Primary Endpoint: Met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to IV administration. Secondary endpoints show clinical improvement consistent with IV administration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd8eaf8f-67ba-4dc1-9ddd-43fba7ffef98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "title",
      "text": "Innovative Trial Accelerated Path Forward",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fe33f2c-faa6-45d9-85bf-aafca75a0c05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "ADAPT-SC Bridging Study",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c7f3d33-ce26-467e-bacd-2a4bb4f85be2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "54cf2a3d-127c-43ae-b7c7-4a9356a273fd",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "KPIs Overview",
      "beatSlug": null,
      "evidence": "Slides 4 and 5 provide an overview of VYVGART launch momentum and innovative trial progress.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 8,
      "from": 5,
      "beatId": "bd3ff8ba-8ace-4d48-9746-6f6353694638",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Propose Solution",
      "beatSlug": null,
      "evidence": "Slides 5 and 8 propose solutions and advance Cusatuzumab in AML.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 3,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "e12419aa-90ba-4699-9605-0331694e3e6a",
      "evidence": "The key takeaways slides reveal an aha moment about the company's strong execution.",
      "position": 0,
      "objective": "What are the key achievements?",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}